Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Stent-Graft procedure offers hope for High-Risk aortic patients

NCT ID NCT00583817

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a less invasive procedure using stent-grafts to treat various types of aortic disease, including aneurysms and dissections. It involves 170 participants who are considered too high-risk for traditional open surgery. The goal is to see if this endovascular approach can reduce deaths and serious complications like stroke.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Endovascular stent-graft implantation (device)
What this could lead to
If successful, this could provide a less invasive treatment option for people with aortic disease who are too high-risk for open surgery.
What could go wrong
This is an early-stage, non-randomized study with no control group, so results may not prove effectiveness. Risks include stroke, death, or incomplete repair.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 170 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2018

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Ascending Arm Protocol: 1. General Inclusion Criteria (Must meet ALL of the following): * Life expectancy greater than 2 years * Suitable arterial anatomy * Absence of systemic disease or allergy that precludes an endovascular repair * Capable of giving informed consent and willingness to comply with follow up schedule * Patient is considered high or prohibitive risk for open surgical repair of the ascending aneurysm or dissection 2. Anatomic Inclusion Criteria * Have ONE of the following 1. Focal aneurysm in ascending aorta 2. Pseudoaneurysms and/or dissections that are distal to the sinotubular junction. 3. A thoracoabdominal aortic aneurysm ≥ 5.0 cm in women and ≥ 5.5 cm in men 4. Have morphology or growth suggestive of immanent rupture * Must meet ALL of the following: 1. Proximal Fixation: 1. \>15 mm aortic length distal to a patent coronary artery or coronary artery bypass that are considered patent and necessary for proper cardiac perfusion. * Proximal fixation may occur in either native aorta or surgical graft * In the setting of the aortic dissection, the proximal fixation must be proximal to the entry tear. * In the setting of aortic dissection, true lumen size must be large enough to allow deployment of the device 2. Aortic diameter at the sinotubular junction \>20 mm and ≤ 38mm 2. Distal Fixation: a length of distal ascending aorta \>5mm proximal to the innominate artery whereby seal and fixation can be achieved (the dissection flap may transcend the arch, but the seal must be achievable within the true lumen of the dissection) 1. Aortic diameter (true lumen diameter in the setting of a dissection) at the innominate artery is ≤ 42mm. If the diameter at the innominate artery is ≥ 38mm the Low Profile version must be used 2. Distance from the ascending aorta to the innominate artery must be \>35mm * Iliac artery access 1. Iliac anatomy must allow for the delivery of the endograft device which is loaded within an 18F-24F sheath. 2. Conduits to the iliac vessels or aorta may be used if deemed necessary 3. In the setting of an aortic dissection, access into the true lumen throughout the length of the aorta must be obtainable Arch Arm Protocol 1. General Inclusion Criteria (Must meet ALL of the following): * Life expectancy greater than 2 years * Suitable arterial anatomy * Absence of systemic disease or allergy that precludes an endovascular repair * Capable of giving informed consent and willingness to comply with follow up schedule * Patient is considered high or prohibitive risk for open surgical repair of the ascending aneurysm or dissection 2. Anatomic Inclusion Criteria * Must meet ALL of the following: 1. Aneurysm of the ascending aorta or aortic arch/proximal descending thoracic aorta that is \>5.5cm or is considered to be at high risk for rupture or dissection given the morphologic characteristics of the aneurysm (or diverticulum). 2. Proximal aortic fixation zone: 1. Native aorta or surgical graft (If surgical graft in ascending aorta, the angulation within the graft must be \<90 degrees) 2. Diameter: 20-42mm 3. Proximal neck length ≥10mm 4. Ascending aortic length \>50mm 5. Must occur distal to coronary arteries and any coronary artery bypass grafts that are considered patent and necessary for proper cardiac perfusion 3. Distal aortic fixation zone: 1. Native aorta or surgical graft 2. Diameter: 20-42mm 3. Distal neck length ≥10mm 4. Supra-aortic trunk (brachiocephalic) vessels 1. Although the prosthesis will typically have two branches, modifications to the design will allow for a single branch or three branches. Thus, it is generally planned that at least one extra-anatomic bypass graft will be done in conjunction (or in a staged fashion) with the procedure. The two vessels incorporated into the endograft repair would most commonly be the innominate artery and left carotid artery. However, the innominate artery may be coupled with the left subclavian artery in the setting of a bovine arch whereby the flow to the left carotid would come from a left subclavian to carotid bypass. Similarly, the left carotid and subclavian artery may be branched, or simply one vessel branched should specific anatomic limitations exist. In such a situation, multiple extra-anatomic bypasses may be necessary. Thus the inclusion criteria are defined for each artery, yet any combination of arteries may be used for a repair. 2. Diameter of vessel(s) to be incorporated into endograft * Innominate artery: 8-22 mm. * Left (or right) common carotid artery: 6-16mm * Left (or right) subclavian artery: 5-20mm * Length of sealing zone ≥ 10mm * Acceptable tortuosity 5. In the setting of an aortic dissection the following criteria must exist: 1. Access into the true lumen from the groin and at least one supra-aortic trunk vessel 2. A sealing zone in the target aorta (or surgical graft) that is proximal to the primary dissection, such that a stent graft would be anticipated to seal off the dissection lumen 3. A sealing zone in the target supra-aortic trunk vessels that is distal to the dissection, anticipated to seal off the dissection lumen, or surgically created 4. A true lumen size large enough to deploy the device and still gain access into the target branches 6. In the setting of a more distal disease, the repair may be coupled with a thoracoabdominal branched device, infrarenal device, and/or internal iliac branch device - typically performed in a staged fashion 7. Iliac anatomy must allow for the delivery of the arch branch device which is loaded within an 18F-24F sheath. Conduits to the iliac vessels or aorta may be used if deemed necessary. Thoracoabdominal Arm Protocol 1. General Inclusion Criteria (Must meet ALL of the following): * Life expectancy greater than 2 years * Suitable arterial anatomy * Absence of systemic disease or allergy that precludes an endovascular repair * Capable of giving informed consent and willingness to comply with follow up schedule 2. Anatomic Inclusion Criteria * Presence of at least one of the following aneurysms is necessary to drive the need for a repair with a fenestrated/branched device: 1. A thoracoabdominal aortic aneurysm ≥ 5 cm in women and ≥ 5.5 cm in men or suggestive of a high risk of rupture as a result of morphology, growth history or symptoms 2. A renal artery aneurysm \> 20 mm (or twice the diameter of native renal artery) 3. An SMA aneurysm \>30 mm * Outside of the "Indications for Use" for commercially available fenestrated or branched endografts approved for use for the treatment of these aneurysms. * Proximal neck 1. Diameter ≤ 40 mm, ≥20 mm 2. Proximal neck length ≥ 10mm. 3. The proximal landing zone may be in a prior endograft or a prior surgical graft. * Iliac Artery 1. Diameter ≥ 7 mm (anticipated diameter following balloon angioplasty, stenting, dottoring, or conduit) or ≥ 6 mm for patients receiving an Low-Profile device. 2. Iliac angulation that will not preclude device delivery or surgical modification of the iliac system 3. For a bifurcated or aorto-monoiliac prosthesis, iliac implantation sites require ≤ 20 mm in diameter and ≥ 20 mm in length * For a straight aorto-aortic prosthesis, distal neck (normal aorta between the aneurysm and iliac bifurcation) ≥ 10 mm in length and ≤ 40 mm in diameter * If a hypogastric branch will be used to treat the common iliac aneurysm 1. The intended common iliac artery is \> 20mm in diameter or the aneurysm has morphology concerning for rupture; and 2. The intended distal fixation site within the internal iliac is ≤ 10mm in diameter. * Renal arteries or other visceral vessels arising from the aorta in an orientation that is evident and measurable from cross-sectional imaging (CT or MR) * Visceral branch diameters (for incorporated vessels) between 4 mm - 11 mm at the intended distal sealing site (thus distal to a visceral artery aneurysm in such circumstances). * Greater than 5 mm of proximal visceral branch length to allow for a seal with the mated device, or the ability to exclude an early branch. * In the setting of an aortic dissection the following criteria must exist: 1. Access into the true lumen from the groin and at least one supra-aortic trunk vessel 2. A sealing zone in the target aorta (or surgical graft) that is proximal to the primary dissection, such that a stentgraft would be anticipated to seal off the dissection lumen 3. A sealing zone in the target supra-aortic trunk vessels that is distal to the dissection, anticipated to seal off the dissection lumen, or surgically created 4. A true lumen size large enough to deploy the device and still gain access into the target branches * In the setting of a more proximal disease, the repair may be coupled with an arch-branched device, thoracic aortic endograft, or surgical aortic repair - typically performed in a staged fashion General Exclusion Criteria 1. Patient can be treated in accordance with the instructions for use with a commercially marketed endovascular prosthesis 2. Patient qualifies for treatment of thoracoabdominal aortic repair under an industry-sponsored clinical trial, open to enrollment at the Massachusetts General Hospital \& Brigham and Women's Hospital 3. Pregnancy 4. History of anaphylactic reaction to contrast material with an inability to properly prophylax the patient appropriately 5. Known sensitivity or allergy to materials of construction of the device (including the materials of the LP device). 6. Body habitus that would inhibit X-ray visualization of the aorta 7. Subject had a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned \<30 days from the endovascular repair 8. Unstable angina 9. Unwilling to comply with follow up schedule 10. Systemic or local infection that may increase the risk of endovascular graft infection 11. An uncorrectable coagulopathy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aortic arch; aneurysm, dissecting are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Aneurysm aneurysm or dilatation of ascending aorta Aneurysm, Ascending Aorta aortic aneurysm Aortic Aneurysm, Thoracoabdominal Aortic Dissection Dissection, Ascending Aorta thoracic aortic aneurysm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.